You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentosan Polysulfate
Accession NumberDB00686  (APRD01175)
TypeSmall Molecule
GroupsApproved
DescriptionA sulfated pentosyl polysaccharide with heparin-like properties. [PubChem]
Structure
Thumb
Synonyms
Pentosan sulfuric polyester
Pentosane polysulfate
Pentosani polysulfas
Pentosano polisulfato
Pentosanpolysulfat
External Identifiers
  • CB-8061
  • PZ 68
  • SP 54
  • UNII-F59P8B75R4
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ElmironCapsule, gelatin coated100 mg/1OralJanssen Pharmaceuticals, Inc.1996-09-26Not applicableUs
ElmironCapsule, gelatin coated100 mg/1OralPhysicians Total Care, Inc.2003-12-17Not applicableUs
ElmironCapsule, gelatin coated100 mg/1OralCardinal Health1996-09-26Not applicableUs
ElmironCapsule100 mgOralJanssen Inc1993-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ComforaSwati Spentose Pvt. Ltd.
FibraseTeofarma
FibrezymBene
HemoclarSanofi Winthrop
HémoclarSanofi-Aventis
Tavan-SPSanofi-Aventis
ThrombocidBene-Chemie
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Calcium pentosan polysulfate
ThumbNot applicableDBSALT001142
Pentosan polysulfate sodium
140207-93-8
ThumbNot applicableDBSALT000991
Categories
UNIIF59P8B75R4
CAS number37300-21-3
WeightAverage: 602.497
Monoisotopic: 601.922340398
Chemical FormulaC10H18O21S4
InChI KeyFCCNSUIJIOOXEZ-SJYYZXOBSA-N
InChI
InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1
IUPAC Name
[(2S,3R,4S,5R)-5-hydroxy-2-{[(3R,4S,5R,6R)-6-hydroxy-4,5-bis(sulfooxy)oxan-3-yl]oxy}-4-(sulfooxy)oxan-3-yl]oxidanesulfonic acid
SMILES
O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[[email protected]](OS(O)(=O)=O)[[email protected]]2OS(O)(=O)=O)[[email protected]](OS(O)(=O)=O)[[email protected]]1OS(O)(=O)=O
Pharmacology
IndicationFor the relief of bladder pain or discomfort associated with interstitial cystitis.
Structured Indications
PharmacodynamicsPentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects.
Mechanism of actionPentosan polysulfate is a polymer of xylose hydrogen sulfate and contains two sulfate groups per carbohydrate monomer. It binds Fibroblast growth factors (FGFs) as well as other heparin-binding growth factors. It has been shown to interact also with the heparin-binding site of FGFR-1. It inhibits the growth of SW13 adrenocortical cells transfected with FGF-4 and tumorigenicity of MCF-7 breast carcinoma cells transfected with FGF-1 or FGF-4.
TargetKindPharmacological actionActionsOrganismUniProt ID
Fibroblast growth factor 2Proteinyes
antagonist
HumanP09038 details
Fibroblast growth factor 1Proteinyes
antagonist
HumanP05230 details
Fibroblast growth factor 4Proteinunknown
inhibitor
HumanP08620 details
Related Articles
AbsorptionSlow
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life4.8 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabPentosan Polysulfate may increase the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
AcenocoumarolPentosan Polysulfate may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Pentosan Polysulfate.Approved
AllylestrenolThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Allylestrenol.Approved
AlprostadilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Alprostadil.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
AltrenogestThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Anagrelide.Approved
AncrodPentosan Polysulfate may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Antithrombin III humanPentosan Polysulfate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Pentosan Polysulfate.Approved
ApremilastApremilast may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
ArdeparinPentosan Polysulfate may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanPentosan Polysulfate may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Azelastine.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
BecaplerminPentosan Polysulfate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Beraprost.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
BivalirudinPentosan Polysulfate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BromfenacBromfenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
BucillamineBucillamine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
ButylphthalideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Butylphthalide.Investigational
CangrelorThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Cangrelor.Approved
CarprofenCarprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
CertoparinPentosan Polysulfate may increase the anticoagulant activities of Certoparin.Approved
ChloroquineChloroquine may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Pentosan Polysulfate.Withdrawn
CilostazolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Cilostazol.Approved
Citric AcidPentosan Polysulfate may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Clopidogrel.Approved, Nutraceutical
CollagenaseThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Collagenase.Approved
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
CurcuminCurcumin may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
DalteparinPentosan Polysulfate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPentosan Polysulfate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
DesirudinPentosan Polysulfate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
DesogestrelThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Desogestrel.Approved
DextranPentosan Polysulfate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Pentosan Polysulfate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Pentosan Polysulfate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Pentosan Polysulfate may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
DicoumarolPentosan Polysulfate may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
DienogestThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Pentosan Polysulfate.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Dipyridamole.Approved
DitazoleDitazole may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
DydrogesteroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
E6201E6201 may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
EbselenEbselen may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Edetic AcidPentosan Polysulfate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Pentosan Polysulfate.Approved
EnoxaparinPentosan Polysulfate may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epinastine.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Pentosan Polysulfate.Approved
eplivanserineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with eplivanserine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epoprostenol.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Eptifibatide.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
EstroneEstrone may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
Ethyl biscoumacetatePentosan Polysulfate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
EtonogestrelThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Pentosan Polysulfate.Approved
exisulindexisulind may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
FenbufenFenbufen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Withdrawn
FluindionePentosan Polysulfate may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Pentosan Polysulfate.Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
FondaparinuxPentosan Polysulfate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPentosan Polysulfate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexatePentosan Polysulfate may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Pentosan Polysulfate.Investigational
GestodeneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Gestrinone.Approved
HeminHemin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
HeparinPentosan Polysulfate may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
HirulogPentosan Polysulfate may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentosan Polysulfate.Approved
IbudilastThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ibudilast.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Icosapent ethyl.Approved, Nutraceutical
idraparinuxPentosan Polysulfate may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ifenprodil.Approved, Withdrawn
IloprostThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Iloprost.Approved, Investigational
IndobufenIndobufen may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
IsoxicamIsoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
Kct 0809Kct 0809 may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Pentosan Polysulfate.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ketanserin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
LepirudinPentosan Polysulfate may increase the anticoagulant activities of Lepirudin.Approved
LevonorgestrelThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Pentosan Polysulfate.Approved
LisofyllineLisofylline may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
LornoxicamLornoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
LynestrenolThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Megestrol acetateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
MestranolMestranol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Pentosan Polysulfate.Experimental
MilrinoneThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Milrinone.Approved
MizoribineMizoribine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
NadroparinPentosan Polysulfate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPentosan Polysulfate may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineNaftifine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Naftopidil.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with NCX 4016.Investigational
NepafenacNepafenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nimesulide.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nintedanib.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nitroaspirin.Investigational
NomegestrolThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Norethisterone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Obinutuzumab.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Pentosan Polysulfate.Approved
OrgoteinOrgotein may increase the anticoagulant activities of Pentosan Polysulfate.Vet Approved
OtamixabanPentosan Polysulfate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
ParecoxibParecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Pentoxifylline.Approved, Investigational
PhenindionePentosan Polysulfate may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonPentosan Polysulfate may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PrasugrelThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Prasugrel.Approved
ProgesteroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Pentosan Polysulfate.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Protein CPentosan Polysulfate may increase the anticoagulant activities of Protein C.Approved
Protein S humanPentosan Polysulfate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePentosan Polysulfate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ramatroban.Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Resveratrol.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
ReviparinPentosan Polysulfate may increase the anticoagulant activities of Reviparin.Approved
RidogrelThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ridogrel.Approved
RivaroxabanPentosan Polysulfate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
S EquolS Equol may decrease the anticoagulant activities of Pentosan Polysulfate.Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SCH-530348The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with SCH-530348.Investigational
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Pentosan Polysulfate.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Sevoflurane.Approved, Vet Approved
SRT501The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with SRT501.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SugammadexSugammadex may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SulindacSulindac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
SulodexidePentosan Polysulfate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Withdrawn
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Pentosan Polysulfate.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tesmilifene.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TiboloneTibolone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ticlopidine.Approved
TinoridineTinoridine may increase the anticoagulant activities of Pentosan Polysulfate.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TipranavirTipranavir may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
TirofibanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tirofiban.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TolmetinTolmetin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
TositumomabThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tositumomab.Approved
TranilastThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tranilast.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Trapidil.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational
TriflusalThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Triflusal.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Pentosan Polysulfate.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Investigational, Withdrawn
Vitamin EVitamin E may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Pentosan Polysulfate.Approved
WarfarinPentosan Polysulfate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPentosan Polysulfate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Pentosan Polysulfate may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
ZeranolZeranol may decrease the anticoagulant activities of Pentosan Polysulfate.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Pentosan Polysulfate.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Pentosan Polysulfate.Withdrawn
Food Interactions
  • Take on an empty stomach, 1 hour before or 2 hours after meals.
References
Synthesis Reference

Pandurang Balwant Deshpande, Parvenkumar Luthra, Anand Kumar Pandey, Dinesh Jayntibhai Paghdar, Phani,Sharma,Gowthamaiah Vemavarapu Govardhana, “PROCESS FOR THE PREPARATION OF PENTOSAN POLYSULFATE OR SALTS THEREOF.” U.S. Patent US20100105889, issued April 29, 2010.

US20100105889
General References
  1. Ghosh P, Smith M: Osteoarthritis, genetic and molecular mechanisms. Biogerontology. 2002;3(1-2):85-8. [PubMed:12014849 ]
External Links
ATC CodesC05BA04G04BX15
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (59.2 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5
Blood Brain Barrier+0.8606
Caco-2 permeable-0.6462
P-glycoprotein substrateNon-substrate0.7185
P-glycoprotein inhibitor IInhibitor0.6326
P-glycoprotein inhibitor IINon-inhibitor0.9889
Renal organic cation transporterNon-inhibitor0.8869
CYP450 2C9 substrateNon-substrate0.9008
CYP450 2D6 substrateNon-substrate0.8275
CYP450 3A4 substrateNon-substrate0.6053
CYP450 1A2 substrateNon-inhibitor0.8007
CYP450 2C9 inhibitorNon-inhibitor0.8387
CYP450 2D6 inhibitorNon-inhibitor0.8982
CYP450 2C19 inhibitorNon-inhibitor0.8044
CYP450 3A4 inhibitorNon-inhibitor0.9891
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.964
Ames testNon AMES toxic0.6383
CarcinogenicityNon-carcinogens0.5703
BiodegradationNot ready biodegradable0.8772
Rat acute toxicity2.3876 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8908
hERG inhibition (predictor II)Non-inhibitor0.7929
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg
Capsule, gelatin coatedOral100 mg/1
Prices
Unit descriptionCostUnit
Elmiron 100 mg capsule3.32USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5180715 No1993-01-192010-01-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-8Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.49 mg/mLALOGPS
logP-2.5ALOGPS
logP-11ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)-2.9ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area322.55 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity96.38 m3·mol-1ChemAxon
Polarizability46.17 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassGlycosyl compounds
Direct ParentO-glycosyl compounds
Alternative Parents
Substituents
  • O-glycosyl compound
  • Disaccharide
  • Sulfuric acid monoester
  • Sulfuric acid ester
  • Alkyl sulfate
  • Sulfate-ester
  • Oxane
  • Organic sulfuric acid or derivatives
  • Secondary alcohol
  • Hemiacetal
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function:
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name:
FGF2
Uniprot ID:
P09038
Molecular Weight:
30769.715 Da
References
  1. Zugmaier G, Favoni R, Jaeger R, Rosen N, Knabbe C: Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors. Ann N Y Acad Sci. 1999;886:243-8. [PubMed:10667230 ]
  2. Mucha S, Melen-Mucha G, Stepien T, Godlewski A, Stepien H: Effects of pentosan polysulfate sodium on the estrogen-induced pituitary prolactinoma in Fischer 344 rats. Oncol Rep. 2002 Nov-Dec;9(6):1385-9. [PubMed:12375053 ]
  3. Pluda JM, Shay LE, Foli A, Tannenbaum S, Cohen PJ, Goldspiel BR, Adamo D, Cooper MR, Broder S, Yarchoan R: Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst. 1993 Oct 6;85(19):1585-92. [PubMed:7692072 ]
  4. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat. 1996;39(1):103-17. [PubMed:8738610 ]
  5. Jerebtsova M, Wong E, Przygodzki R, Tang P, Ray PE: A novel role of fibroblast growth factor-2 and pentosan polysulfate in the pathogenesis of intestinal bleeding in mice. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H743-50. Epub 2006 Oct 27. [PubMed:17071728 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
S100 protein binding
Specific Function:
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name:
FGF1
Uniprot ID:
P05230
Molecular Weight:
17459.58 Da
References
  1. Pascu C, Ljungh A, Wadstrom T: Staphylococci bind heparin-binding host growth factors. Curr Microbiol. 1996 Apr;32(4):201-7. [PubMed:8867461 ]
  2. Zenjari C, Boilly-Marer Y, Desbiens X, Oudghir M, Hondermarck H, Boilly B: Experimental evidence for FGF-1 control of blastema cell proliferation during limb regeneration of the amphibian Pleurodeles waltl. Int J Dev Biol. 1996 Oct;40(5):965-71. [PubMed:8946244 ]
  3. Jerebtsova M, Wong E, Przygodzki R, Tang P, Ray PE: A novel role of fibroblast growth factor-2 and pentosan polysulfate in the pathogenesis of intestinal bleeding in mice. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H743-50. Epub 2006 Oct 27. [PubMed:17071728 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Heparin binding
Specific Function:
Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal limb and cardiac valve development during embryogenesis.
Gene Name:
FGF4
Uniprot ID:
P08620
Molecular Weight:
22047.355 Da
References
  1. Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst. 1992 Nov 18;84(22):1716-24. [PubMed:1279186 ]
  2. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat. 1996;39(1):103-17. [PubMed:8738610 ]
  3. Wellstein A, Zugmaier G, Califano JA 3rd, Kern F, Paik S, Lippman ME: Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst. 1991 May 15;83(10):716-20. [PubMed:1708834 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46